Benefit-Risk Assessment of Obesity Drugs: Focus on Glucagon-like Peptide-1 Receptor Agonists.

Christensen, Rasmus M

Benefit-Risk Assessment of Obesity Drugs: Focus on Glucagon-like Peptide-1 Receptor Agonists. [electronic resource] - Drug safety 08 2019 - 957-971 p. digital

Publication Type: Journal Article; Research Support, Non-U.S. Gov't; Review

1179-1942

10.1007/s40264-019-00812-7 doi


Animals
Glucagon-Like Peptides--adverse effects
Humans
Hypoglycemic Agents
Liraglutide--adverse effects
Obesity--drug therapy
Randomized Controlled Trials as Topic
Risk Assessment
Glucagon-Like Peptide-1 Receptor Agonists